NAREB final meeting! Our first European Project is ending after four years contributing to develop new nanotherapeutics.

The company´s main contribution in this Project, Nanotherapeutics for Antibiotics Resistant Emerging Bacterial pathogens, is related to physicochemical characterization of nanodelivery systems.

This is a biological and immunological characterization, both in vitro and in vivo, and biodistribution in order to test the safety of the nanosystems developed and to validate cell targeting.

 

Sign up for our monthly newsletter: